C 20- you will have a voice at the shareholders meeting…use it for good.
If LL is what we originally thought it to be, why does it consistently fail on trials? Either the trials are poorly designed by MANAGEMENT or it doesn’t work for COVID. That doesn’t make it a bad drug, it means that management is obtuse.
It wasn’t a poor decision to pursue COVID. It was a poor decision to back burner the closest money making venture, HIV, while pursuing COVID. No experienced pharma executives went after M2M …it was a total wasted effort. What was learned from that failure that was employed in S2C?…nothing because that failed also. We know it works for HIV, but others are catching up. LH raw numbers do not look good and NPs twisting of the metrics will be rejected by science. That is the major problem with NP he does not understand the scientific method and thinks anecdotal data and voodoo analysis will fool the scientific community. He will not accept the way things need to be done, which cause failure at every turn. Otherwise name a success.